Is adjuvant pembrolizumab (Keytruda) appropriate for a patient with resected cecal adenocarcinoma that is deficient in MLH1, MSH6, and PMS2 and harbors a BRAF V600E mutation?

Adjuvant Pembrolizumab for Resected Cecal Cancer with dMMR and BRAF V600E Mutation

Yes, adjuvant pembrolizumab is highly appropriate and should be strongly considered for this patient with resected cecal adenocarcinoma showing deficient mismatch repair (loss of MLH1, MSH6, and PMS2) and BRAF V600E mutation.

Rationale Based on FDA Approval and Guidelines

Pembrolizumab is FDA-approved for multiple solid tumors based on biomarker status, though the specific indication for adjuvant colorectal cancer is not explicitly listed in the provided FDA label 1. However, the tumor's molecular profile—particularly the dMMR/MSI-H status—is the critical determinant here, not the BRAF mutation status.

Key Molecular Features Supporting Pembrolizumab Use

The dMMR status (loss of MLH1, MSH6, and PMS2) is the primary driver for immunotherapy benefit:

• dMMR/MSI-H colorectal cancers exhibit high tumor mutational burden and strong immunogenicity, making them exquisitely sensitive to PD-1 blockade 2, 3, 4, 5
• Multiple recent case reports demonstrate dramatic responses to pembrolizumab in dMMR colorectal cancer, including complete pathological responses and durable disease-free survival exceeding 26-38 months 6, 2, 4, 5
• The NCCN guidelines explicitly state that MSI-H/dMMR tumors with BRAF V600E should preferentially receive checkpoint inhibitor therapy 7

The BRAF V600E Mutation Context

The concurrent BRAF V600E mutation does not contraindicate pembrolizumab—in fact, it may enhance the rationale:

• BRAF V600E is primarily a poor prognostic marker in MSS (microsatellite stable) tumors, conferring worse survival after recurrence 7
• However, in the dMMR/MSI-H context, the BRAF mutation identifies a high-risk subgroup that particularly benefits from immunotherapy 6, 2
• Recent evidence suggests BRAF V600E may contribute to an inflamed tumor microenvironment that enhances response to checkpoint inhibition 8
• Case reports specifically document exceptional responses to pembrolizumab in dMMR + BRAF V600E colorectal cancer, with one patient achieving complete response maintained for over 26 months 6

Clinical Decision Algorithm

For this specific patient, proceed as follows:

1. Confirm dMMR status through immunohistochemistry showing loss of MLH1, MSH6, and PMS2 (already done)
2. Consider germline testing to distinguish Lynch syndrome from sporadic dMMR (BRAF V600E mutation suggests sporadic, likely due to MLH1 promoter methylation) 2, 9
3. Initiate adjuvant pembrolizumab at standard dosing (typically 200 mg IV every 3 weeks or 400 mg every 6 weeks)
4. Monitor for immune-related adverse events, which are generally manageable in elderly patients 2

Supporting Evidence from Recent Cases

The most compelling recent evidence comes from multiple 2025-2026 case reports demonstrating:

• A 77-year-old woman with dMMR, BRAF V600E cecal cancer achieved 38 months disease-free survival on adjuvant envafolimab (another PD-1 inhibitor) without significant toxicity 2
• An 85-year-old with aggressive dMMR + BRAF V600E metastatic colon cancer achieved complete response with pembrolizumab maintenance after brief BRAF inhibitor exposure, remaining progression-free for 26+ months 6
• A 70-year-old with locally advanced MSI-H, BRAF V600E ascending colon cancer achieved complete pathological response (Grade 3) with neoadjuvant pembrolizumab 4

Important Caveats

Distinguish this from MSS BRAF-mutant disease:

• The evidence showing poor outcomes with BRAF V600E mutations applies primarily to MSS tumors 7
• In MSS disease, BRAF V600E predicts resistance to anti-EGFR therapy and poor prognosis
• The dMMR status fundamentally changes the biology and treatment paradigm

Germline testing considerations:

• While BRAF V600E strongly suggests sporadic (non-Lynch) disease, germline testing should still be performed 2, 9
• Isolated PMS2 loss or combined MLH1/PMS2 loss patterns are most common in sporadic dMMR 9
• The unusual pattern of MLH1, MSH6, AND PMS2 loss warrants careful pathology review

Treatment duration:

• Optimal duration of adjuvant pembrolizumab in this setting is not definitively established
• Extrapolating from melanoma data and case reports, 6-12 months of therapy is reasonable 2

The combination of dMMR/MSI-H status with BRAF V600E mutation in this resected cecal cancer represents a strong indication for adjuvant pembrolizumab, with emerging evidence suggesting excellent outcomes in this molecular subgroup.